Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 11.79B 10.23B 9.58B 8.76B 16.55B 1,123B 16.76B 112B 43.99B 561B 44.27B 43.31B 1,868B P/E 2026 *
-80.8x
P/E 2027 * 81.1x
Enterprise Value 11.27B 9.78B 9.16B 8.37B 15.81B 1,073B 16.02B 107B 42.03B 536B 42.3B 41.38B 1,785B EV / Sales 2026 *
7.38x
EV / Sales 2027 * 5.06x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.73%
1 week+3.50%
Current month+9.21%
1 month-3.61%
3 months-5.44%
6 months+6.86%
Current year-12.36%
1 week 461.25
Extreme 461.25
524.45
1 month 447.01
Extreme 447.01
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 339.31
Extreme 339.31
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 7.27
Extreme 7.27
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Director

1,220 0.0053%
23/2/26 Fiscal year

Director

5,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%+3.50%+50.94%+162.42% 11.88B
-3.25%+13.72%+52.49%+88.86% 64.9B
+0.69%+0.96%+29.39%+68.41% 54.05B
-1.07%-1.79%-18.07%-14.36% 23.16B
+33.86%+30.60%+19.14%+502.77% 21.46B
+6.62%+13.94%+47.04%+0.66% 21.25B
-0.79%+1.79%+36.31%-25.84% 17.94B
-3.37%+25.85%+213.21%+369.13% 17.03B
+4.43%+9.65%+32.69%+668.84% 14.99B
-7.94%-6.74%+38.42%+157.52% 14.25B
Average +2.85%+5.32%+50.16%+197.84% 26.09B
Weighted average by Cap. +2.08%+6.38%+45.65%+153.14%

Financials

2026 *2027 *
Net sales 1.53B 1.32B 1.24B 1.13B 2.14B 145B 2.17B 14.51B 5.69B 72.64B 5.73B 5.61B 242B 2.14B 1.86B 1.74B 1.59B 3.01B 204B 3.05B 20.39B 8B 102B 8.05B 7.88B 340B
Net income -184M -160M -149M -137M -258M -17.51B -261M -1.75B -686M -8.75B -690M -675M -29.13B 200M 174M 163M 149M 281M 19.05B 284M 1.9B 746M 9.52B 751M 735M 31.68B
Net Debt -525M -455M -426M -390M -736M -49.97B -746M -4.99B -1.96B -24.96B -1.97B -1.93B -83.09B -943M -819M -766M -701M -1.32B -89.85B -1.34B -8.97B -3.52B -44.89B -3.54B -3.46B -149B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
06/08/26 USD 510.36 -0.73% 296,763
05/08/26 USD 514.12 +1.29% 349,534
04/08/26 USD 507.56 +5.30% 442,367
03/08/26 USD 482.00 +3.14% 463,916
31/07/26 USD 467.32 -5.23% 795,264
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
510.36USD
Average target price
678.06USD
Spread / Average Target
+32.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock